<DOC>
	<DOCNO>NCT00002217</DOCNO>
	<brief_summary>The purpose study test effectiveness Combivir plus abacavir plus 141W94 patient previously use anti-HIV drug .</brief_summary>
	<brief_title>A Study Combivir Plus Abacavir Plus 141W94 Patients Who Previously Have Used Anti-HIV Drugs</brief_title>
	<detailed_description>In open-label study antiretroviral-experienced patient receive Combivir ( 3TC/AZT tablet ) plus 1592U89 ( abacavir ) 141W94 twice daily 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : CD4 count great 50 cells/mm3 . HIV RNA le 50,000 copies/ml . No active AIDS ( exclude CD4 count le 200 cells/mm3 ) . Ability comply dose schedule protocol evaluation . Prior Medication : Allowed : AZT nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active AIDS ( exclude CD4 count le 200 ) . Malabsorption syndrome affect drug absorption . Serious medical condition would compromise safety patient . Concurrent Medication : Excluded : AZT NNRTIs . More 1 week treatment protease inhibitor . Enrollment investigational drug protocol . Patients follow prior condition exclude : History clinically relevant pancreatitis hepatitis within past 6 month . Required : Antiretroviral therapy either single double reverse transcriptase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>